Characteristics of patients with Lynch syndrome
| All patients (n=137) | Patients with non-endometrioid endometrial cancer (n=27) | ||
| Age, years | Median | 49 | 49 |
| Range | 28–75 | 31–73 | |
| Gene mutation | MLH1 | 40 (29.2%) | 5 (18.5%) |
| MSH2 | 36 (26.3%) | 8 (29.6%) | |
| MSH6 | 17 (12.4%) | 4 (14.8%) | |
| Unknown | 44 (32.1%) | 10 (37%) | |
| Stage | IA | 69 (50.3%) | 14 (51.8%) |
| IB | 18 (13.1%) | 4 (14.8%) | |
| II | 8 (5.8%) | 3 (11.1%) | |
| III | 9 (6.6%) | 5 (18.5%) | |
| IV | 1 (0.7%) | 1 (3.7%) | |
| Unknown | 32 (24.2%) | 0 | |
| Grade | G1 | 50 (36.5%) | 0 |
| G2 | 30 (21.9%) | 0 | |
| G3 | 28 (20.4%) | 27 (100%) | |
| Unknown | 29 (21.2%) | 0 | |
| Histotype | Endometrioid | 110 (80.2%) | 0 |
| Serous papillary | 10 (7.3%) | 10 (37.1%) | |
| Clear cell | 7 (5.1%) | 7 (25.9%) | |
| Undifferentiated | 3 (2.2%) | 3 (11.1%) | |
| Mixed | 7 (5.1%) | 7 (25.9%) | |
| Follow-up, months | Median | 135.3 | 134 |
| Range | 10–550 | 1–295 |